Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals

Inclusion Criteria Patients must have: HIV positivity confirmed by Western blot. CD4 count of 100 - 500 cells/mm3 on a morning draw within 3 weeks prior to study entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: Concurrent neoplasms other than basal cell carcinoma of the skin, in situ carcinoma of the cervix, or nondisseminated Kaposi's sarcoma. Hemophilia or other clotting disorders. Major organ allograft. Significant cardiac, hepatic, renal, or CNS disease. Prior Medication: Excluded: Antiretroviral agents within 2 months prior to study entry. Known anti-HIV medication within 60 days prior to study entry. Prior immunomodulators (e.g., systemic steroids, interferons, or interleukins) or other chemotherapy. Prior Treatment: Excluded: Prior radiation therapy. Active substance abuse.